Evidence map›Paper›PMID 38733554›Full record

ArticleDiscover oncology2024

Identification of NINJ1 as a novel prognostic predictor for retroperitoneal liposarcoma.

Yu Zhao, Da Qin, Xiangji Li, Tiange Wang, Tong Zhang, Xiaosong Rao, Li Min, Zhiyi Wan, Chenghua Luo, Mengmeng Xiao

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03838718 (REtroperitoneal SArcoma Registry), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03838718 recruitingnot on this map

REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group

Typeobservational_patient_registrySponsorFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRan2016 to 2030Enrolled2,000ConditionsRetroperitoneal Sarcoma
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The role of NINJ1 in diseases.Cell death discovery · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu Zhao *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, China.
Da Qin *Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, China.
Xiangji LiDepartment of Retroperitoneal Tumor Surgery, International Hospital, Peking University, Beijing, China.
Tiange WangDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, China.
Tong ZhangDepartment of Pathology, International Hospital, Peking University, Beijing, China.
Xiaosong RaoDepartment of Pathology, International Hospital, Peking University, Beijing, China.
Li MinDepartment of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, China.
Zhiyi WanCollege of Biological Sciences, China Agricultural University, Beijing, China.
Chenghua LuoDepartment of Retroperitoneal Tumor Surgery, Peking University People's Hospital, Beijing, China. pkuihlch@163.com.
Mengmeng XiaoDepartment of Retroperitoneal Tumor Surgery, International Hospital, Peking University, Beijing, China. xiaomengmeng@pku.edu.cn.

Funding

Beijing Municipal Administration of Hospitals' Youth Program QML20180108Beijing Municipal Science and Technology Project Z191100006619081Beijing Science and Technology Nova Program Z191100001119128National Natural Science Foundation of China 82073390Peking University International Hospital Research Grant YN2019QN11
6 · The paper itself

Abstract

backgroundRetroperitoneal liposarcoma (RPLS) is known for its propensity for local recurrence and short survival time. We aimed to identify a credible and specific prognostic biomarker for RPLS.

methodsCases from The Cancer Genome Atlas (TCGA) sarcoma dataset were included as the training group. Co-expression modules were constructed using weighted gene co-expression network analysis (WGCNA) to explore associations between modules and survival. Survival analysis of hub genes was performed using the Kaplan-Meier method. In addition, independent external validation was performed on a cohort of 135 Chinese RPLS patients from the REtroperitoneal SArcoma Registry (RESAR) study (NCT03838718).

resultsA total of 19 co-expression modules were constructed based on the expression levels of 26,497 RNAs in the TCGA cohort. Among these modules, the green module exhibited a positive correlation with overall survival (OS, p = 0.10) and disease-free survival (DFS, p = 0.06). Gene set enrichment analysis showed that the green module was associated with endocytosis and soft-tissue sarcomas. Survival analysis demonstrated that NINJ1, a hub gene within the green module, was positively associated with OS (p = 0.019) in the TCGA cohort. Moreover, in the validation cohort, patients with higher NINJ1 expression levels displayed a higher probability of survival for both OS (p = 0.023) and DFS (p = 0.012). Multivariable Cox analysis further confirmed the independent prognostic significance of NINJ1.

conclusionsWe here provide a foundation for the establishment of a consensus prognostic biomarker for RPLS, which should not only facilitate medical treatment but also guide the development of novel targeted drugs.

Indexed as

Gene expressionNINJ1Overall survivalPrognosisRetroperitoneal liposarcoma

Identifiers

PMID38733554
PMCPMC11088571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.